<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer - Lawrie, TA - 2013 | Cochrane Library</title> <meta content="Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer - Lawrie, TA - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010482.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer - Lawrie, TA - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010482.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010482.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer" name="citation_title"/> <meta content="Theresa A Lawrie" name="citation_author"/> <meta content="The Evidence‐Based Medicine Consultancy Ltd" name="citation_author_institution"/> <meta content="tesslawrie@gmail.com" name="citation_author_email"/> <meta content="Roy Rabbie" name="citation_author"/> <meta content="Epsom and St Helier University Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Clemens Thoma" name="citation_author"/> <meta content="Springer Nature" name="citation_author_institution"/> <meta content="Jo Morrison" name="citation_author"/> <meta content="Musgrove Park Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD010482.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010482.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010482.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010482.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibiotics, Antineoplastic [*therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Carboplatin [administration &amp; dosage]; Carcinoma, Ovarian Epithelial; Doxorubicin [*analogs &amp; derivatives, therapeutic use]; Drug Administration Schedule; Neoplasms, Glandular and Epithelial [*drug therapy]; Ovarian Neoplasms [*drug therapy]; Paclitaxel [administration &amp; dosage]; Polyethylene Glycols [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010482.pub2&amp;doi=10.1002/14651858.CD010482.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010482\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010482\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010482.pub2",title:"Pegylated liposomal doxorubicin for first\\u2010line treatment of epithelial ovarian cancer",firstPublishedDate:"Oct 21, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010482.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010482.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010482.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010482.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010482.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010482.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010482.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010482.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010482.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010482.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6310 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010482.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0007"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0001"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0002"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0003"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0004"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0005"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-sec1-0006"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/appendices#CD010482-sec1-0012"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/table_n/CD010482StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/table_n/CD010482StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#CD010482-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Theresa A Lawrie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#CD010482-cr-0003">Roy Rabbie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#CD010482-cr-0004">Clemens Thoma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information#CD010482-cr-0005">Jo Morrison</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information/en#CD010482-sec1-0015">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010482.pub2">https://doi.org/10.1002/14651858.CD010482.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010482-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010482-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010482-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010482-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010482-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010482-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010482-abs-0001" lang="en"> <section id="CD010482-abs1-0001"> <h3 class="title" id="CD010482-abs1-0001">Background</h3> <p>Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first‐line management. Currently, the recommended standard first‐line chemotherapy is platinum‐based, usually consisting of carboplatin and paclitaxel (PAC/carbo). Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin that is associated with fewer and less severe side effects than are seen with non‐modified doxorubicin. In combination with carboplatin, PLD has recently been shown to improve progression‐free survival compared with PAC/carbo in women with relapsed, platinum‐sensitive EOC. It is therefore important to know whether any survival benefit can be attributed to PLD when it is used in the first‐line setting. </p> </section> <section id="CD010482-abs1-0002"> <h3 class="title" id="CD010482-abs1-0002">Objectives</h3> <p>To evaluate the role of PLD, alone or in combination, in first‐line chemotherapy for women with EOC. </p> </section> <section id="CD010482-abs1-0003"> <h3 class="title" id="CD010482-abs1-0003">Search methods</h3> <p>We searched The Cochrane Gynaecological Cancer Group's Trial Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE from January 1990 to February 2013. In addition, we searched online trial registries for ongoing trials and abstracts of studies presented at relevant scientific meetings from 2000 onwards. </p> </section> <section id="CD010482-abs1-0004"> <h3 class="title" id="CD010482-abs1-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that compared PLD alone or in combination with other agent/s (e.g. carboplatin) versus other agent/s for first‐line chemotherapy in women with EOC who may or may not have undergone primary cytoreductive surgery. </p> </section> <section id="CD010482-abs1-0005"> <h3 class="title" id="CD010482-abs1-0005">Data collection and analysis</h3> <p>Two review authors independently selected trials, extracted data and assessed the risk of bias for each included trial. We obtained updated trial data when possible. </p> </section> <section id="CD010482-abs1-0006"> <h3 class="title" id="CD010482-abs1-0006">Main results</h3> <p>We included two large trials. One trial compared three‐weekly PLD and carboplatin (PLD/carbo) with PAC/carbo. The other trial included four experimental arms, one of which was PLD plus PAC/carbo, that were compared with the standard PAC/carbo regimen. We did not combine results of these two trials in the meta‐analysis. We considered the two studies to be at low risk of bias. </p> <p>For the comparison PLD/carbo versus PAC/carbo (820 women; stages Ic to IV), no statistically significant differences in progression‐free survival (PFS) (hazard ratio [HR] 1.01, 95% confidence interval [CI] 0.85 to 1.19) or overall survival (OS) (HR 0.94, 95% CI 0.78 to 1.13) were noted between study arms. Severe anaemia (risk ratio [RR] 2.74, 95% CI 1.54 to 4.88) and thrombocytopenia (RR 8.09, 95% CI 3.93 to 16.67) were significantly more common with PLD/carbo, whereas alopecia (RR 0.09, 95% CI 0.06 to 0.14) and severe neurotoxicity (RR 0.09, 95% CI 0.01 to 0.66) were significantly more common with PAC/carbo. Quality of life scores were not significantly different. </p> <p>For the comparison PLD/PAC/carbo versus PAC/carbo (1726 women; stage III/IV), it is important to note that PLD was given for alternate cycles only (i.e. every 6 weeks). No statistically significant difference in PFS (HR 0.98, 95% CI 0.88 to 1.09) or OS (HR 0.95, 95% CI 0.84 to 1.08) between these two treatment arms was reported. However, women in the triplet arm experienced significantly more severe haematological adverse events (anaemia, thrombocytopenia, neutropenia and febrile neutropenia) compared with those given standard treatment. </p> <p>No RCTs evaluated single‐agent PLD for first‐line treatment of EOC.</p> </section> <section id="CD010482-abs1-0007"> <h3 class="title" id="CD010482-abs1-0007">Authors' conclusions</h3> <p>PLD/carbo is a reasonable alternative to PAC/carbo for the first‐line treatment of EOC. Although three‐weekly PLD/carbo may be associated with increased dose delays and discontinuations compared with the standard PAC/carbo regimen, it might be more acceptable to women who wish to avoid alopecia or those at high risk of neurotoxicity. No survival benefits appear to be associated with the alternating triplet regimen, and the additional toxicity associated with adding PLD to PAC/carbo limits further investigation. Further studies are needed to establish the safest, most effective PLD/carbo regimen for newly diagnosed disease. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010482-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010482-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010482-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010482-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010482-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010482-abs-0007">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010482-abs-0006" lang="en"> <h3>A modified formulation of doxorubicin for the treatment of newly diagnosed ovarian cancer </h3> <p><i>Background</i> </p> <p>PLD is an improved formulation of an anticancer drug that has been around since the 1960s. When used with carboplatin (carbo), it has been shown to improve survival in women with epithelial ovarian cancer (EOC) that has come back (relapsed) six months or longer after the last platinum (carbo)‐based treatment. </p> <p><i>Methods</i> </p> <p>We wanted to find out whether PLD was also useful for the treatment of newly diagnosed EOC. We searched the literature from 1990 to January 2013 for relevant studies and included two studies in this review. </p> <p><i>Study characteristics</i> </p> <p>One study compared PLD plus carbo given to women every three weeks versus the standard treatment (paclitaxel (PAC)/carbo every three weeks), and the other added PLD to the standard treatment and compared it with standard treatment only (the latter study also included other treatments not relevant to this review). These studies spanned three years and included 820 and 4100 women, respectively. Most women in these studies had advanced cancer and had undergone surgery to remove as much of the cancer as possible. </p> <p><i>Key findings</i> </p> <p>Women receiving the PLD/carbo treatment and those given the standard treatment survived for a similar period, but PLD/carbo caused more women to experience low blood counts (anaemia and low platelets) that often led to a delay in treatment or the need to stop treatment. However, PLD/carbo caused far fewer women to experience hair loss and neuropathy (nerve damage causing symptoms such as tingling, numbness, pain, loss of sensation and/or coordination), and so it might help women who find these side effects unacceptable or intolerable. We concluded that three‐weekly PLD/carbo is a reasonable alternative to standard platinum‐based treatment for newly diagnosed EOC, but more research is needed to establish the safest and most effective dosage and dose frequency. </p> <p>Adding PLD to standard treatment (PAC/carbo) every six weeks did not help women with newly diagnosed ovarian cancer survive longer and was associated with worse effects on blood counts that increased the chance of infection; therefore this triple drug treatment cannot be recommended. </p> <p><i>Quality of the evidence</i> </p> <p>We considered the evidence related to survival of women after they are treated with PLD/carbo or PAC/carbo, and the evidence related to adverse drug effects to be of high quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010482-sec1-0007" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010482-sec1-0007"></div> <h3 class="title" id="CD010482-sec1-0008">Implications for practice</h3> <section id="CD010482-sec1-0008"> <p>Three‐weekly PLD/carbo is a reasonable alternative to PAC/carbo in the first‐line treatment of EOC, particularly for women in whom PAC‐induced alopecia and/or neuropathies are unacceptable. However, haematological adverse events, such as anaemia and thrombocytopenia, occur more frequently with PLD, and the availability and cost of appropriate supportive therapy to ameliorate these toxicities need to be considered. The alternating triplet regimen (PLD/PAC/carbo) is associated with significantly more toxicity than is standard treatment (PAC/carbo), with no significant improvement in survival, and therefore has no place in clinical practice. </p> </section> <h3 class="title" id="CD010482-sec1-0009">Implications for research</h3> <section id="CD010482-sec1-0009"> <p>The following studies of PLD for first‐line treatment of ovarian cancer may be of value. </p> <p> <ul id="CD010482-lst1-0012"> <li> <p>Adding bevacizumab to PLD/carbo compared with other bevacizumab combinations.</p> </li> <li> <p>Alternating PLD and PAC (weekly or three‐weekly) with carbo.</p> </li> <li> <p>Three‐weekly PLD/carbo regimens compared with four‐weekly regimens.</p> </li> <li> <p>Single‐agent PLD in women for whom platinum‐based treatment is unsuitable.</p> </li> <li> <p>A network meta‐analysis review with direct and indirect comparisons of the various chemotherapy options available for primary EOC. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010482-sec1-0001" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010482-sec1-0001"></div> <div class="table" id="CD010482-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PLD/carbo compared with PAC/carbo for first‐line treatment of epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women with newly diagnosed EOC (stage Ic to IV) </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> PLD (30 mg/m²)/carbo every three weeks </p> <p><b>Comparison:</b> PAC/carbo every three weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk*</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b>¹ </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.01</p> <p>(0.85 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OS</b>² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.94</p> <p>(0.78 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>820</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anaemia (grade 3/4)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> <p>(57 to 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.74</p> <p>(1.54 to 4.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenia (grade 3/4)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>162 per 1000</p> <p>(79 to 333)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 8.09</p> <p>(3.93 to 16.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alopecia (grade 2)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>595 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>54 per 1000</p> <p>(36 to 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09</p> <p>(0.06 to 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuropathy (grade 3/4)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000</p> <p>(0 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09</p> <p>(0.01 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The assumed risk is the median risk for the control group in the one included study. <b>CI:</b> Confidence interval; <b>HR:</b> Hazard Ratio; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>¹Relative median PFS in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> (all participants) was 16.8 months and 19.0 months for PAC/carbo and PLD/carbo, respectively (published 2011 data). <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> also performed exploratory analyses of a high‐risk group (defined as stage IV, or stage III with residual disease &gt; 1 cm). The relative median PFS for this high‐risk group was 11 versus 11.8 months for PAC/carbo and PLD/carbo, respectively (unpublished 2013 data). </p> <p>²Relative median OS in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> (all participants) was 53.2 months and 61.6 months for PAC/carbo and PLD/carbo, respectively (published 2011 data). The relative median PFS for the high‐risk group defined above was 29 months versus 30.3 months for PAC/carbo and PLD/carbo, respectively (unpublished 2013 data). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010482-sec1-0002" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010482-sec1-0002"></div> <section id="CD010482-sec2-0001"> <h3 class="title" id="CD010482-sec2-0001">Description of the condition</h3> <p>Worldwide, nearly 225,000 women are diagnosed with ovarian cancer each year, making it the eighth most common cancer in women. The estimated risk of getting the disease is approximately 1% in developed countries (Europe, Northern America, Australia/New Zealand and Japan) and 0.5% in the rest of the world (<a href="./references#CD010482-bbs2-0019" title="FerlayJ , ShinHR , BrayF , FormanD , MathersC , ParkinDM . GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Lyon, France. ">GLOBOCAN 2008</a>).    </p> <p>Epithelial ovarian cancer (EOC) usually has a relatively asymptomatic onset and, initially, an inconspicuous progression. Symptoms characteristically are non‐specific and include abdominal swelling and pain, early satiety, weight loss, changes in bowel habit and urinary urgency and frequency (<a href="./references#CD010482-bbs2-0030" title="National Institute for Health and Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer (CG122). London: National Institute for Health and Clinical Excellence2011. ">NICE 2011</a>). This absence of a clear clinical profile results in diagnosis with advanced‐stage disease for most women (FIGO (International Federation of Gynecology and Obstetrics) III and IV; <a href="./references#CD010482-bbs2-0016" title="FIGOCinGO . Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics2009;105(1):3‐4. ">FIGO 2009</a>), giving EOC the poorest prognosis of all gynaecological cancers, with five‐year relative survival rates of only 37% and 54% in Europe and America, respectively (<a href="./references#CD010482-bbs2-0015" title="SantM , AllemaniC , SantaquilaniM , KnijnA , MarchesiF , CapocacciaR . EUROCARE‐4. Survival of cancer patients diagnosed in 1995‐1999. Results and commentary. European Journal of Cancer2009;45(6):931‐91. ">EUROCARE‐4 2009</a>; <a href="./references#CD010482-bbs2-0035" title="KosaryCL . Chapter 16: Cancer of the ovary. In: RiesLAG , YoungJL , KeelGE , EisnerMP , LinYD , HornerM‐J editor(s). Cancer Survival Among Adults: US SEER Program, 1988‐2001. Bethesda: US Department of Health and Human Services; National Cancer Institute, 2007:133‐44. ">SEER 2007</a>). However, if women are diagnosed at FIGO stage I, they have a 90% chance of surviving the next five years (<a href="./references#CD010482-bbs2-0035" title="KosaryCL . Chapter 16: Cancer of the ovary. In: RiesLAG , YoungJL , KeelGE , EisnerMP , LinYD , HornerM‐J editor(s). Cancer Survival Among Adults: US SEER Program, 1988‐2001. Bethesda: US Department of Health and Human Services; National Cancer Institute, 2007:133‐44. ">SEER 2007</a>). The need to improve detection of early disease was recognised over 30 years ago, and this recognition led to the development of screening protocols based on vaginal examination, measurement of serum CA125 levels and ultrasonography (<a href="./references#CD010482-bbs2-0009" title="CampbellS , BhanV , RoystonP , WhiteheadMI , CollinsWP . Transabdominal ultrasound screening for early ovarian cancer. BMJ1989;299(6712):1363‐7. ">Campbell 1989</a>; <a href="./references#CD010482-bbs2-0023" title="JacobsI , BridgesJ , ReynoldsC , StabileI , KemsleyP , GrudzinskasJ , et al. Multimodal approach to screening for ovarian cancer. The Lancet1988;331(8580):268‐71. ">Jacobs 1988</a>). However, although studies using refined diagnostic techniques, such as transvaginal ultrasound, are still under way (<a href="./references#CD010482-bbs2-0028" title="MenonU , Gentry‐MaharajA , HallettR , RyanA , BurnellM , SharmaA , et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The Lancet Oncology2009;10(4):327‐40. ">Menon 2009</a>), it is not yet clear whether implementation of a screening programme would lower mortality rates and benefit affected women. Around 90% of all ovarian malignancies are EOC; other types include germ cell, stromal cell and Müllerian tumours (<a href="./references#CD010482-bbs2-0035" title="KosaryCL . Chapter 16: Cancer of the ovary. In: RiesLAG , YoungJL , KeelGE , EisnerMP , LinYD , HornerM‐J editor(s). Cancer Survival Among Adults: US SEER Program, 1988‐2001. Bethesda: US Department of Health and Human Services; National Cancer Institute, 2007:133‐44. ">SEER 2007</a>). Primary diagnostic tests for EOC consist of measurement of serum CA125 levels and ultrasonography. If disease is suspected, women undergo imaging with computed tomography (CT), magnetic resonance imaging (MRI) and biopsy or exploratory laparotomy, when the tumour is histologically classified and staged and all macroscopic disease is removed (<a href="./references#CD010482-bbs2-0030" title="National Institute for Health and Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer (CG122). London: National Institute for Health and Clinical Excellence2011. ">NICE 2011</a>).  </p> <p>Further standard treatment is disease‐dependent. Women who present with low‐grade stage I tumours might not undergo chemotherapy, those with high‐grade stage I disease may receive platinum‐based therapy alone and those with disease at all other stages receive intravenous platinum‐based chemotherapy, often in combination with paclitaxel (PAC) (<a href="./references#CD010482-bbs2-0030" title="National Institute for Health and Clinical Excellence. Ovarian cancer: the recognition and initial management of ovarian cancer (CG122). London: National Institute for Health and Clinical Excellence2011. ">NICE 2011</a>). Carboplatin (Carbo) is favoured over cisplatin because it is less toxic and has equivalent efficacy (<a href="./references#CD010482-bbs2-0029" title="National Institute for Health and Clinical Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55). London: National Institute for Health and Clinical Excellence,2003. ">NICE 2003</a>). Bevacizumab, an angiogenesis inhibitor, has been approved for use in advanced EOC in Europe (<a href="./references#CD010482-bbs2-0014" title="European Medicines Agency. Avastin (bevacizumab) product page. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/000582/WC500029271.pdf. ">EMA 2011</a>) and is now an option for many women. Adding bevacizumab as concurrent and maintenance therapy to the standard PAC/carbo regimen has been shown to improve progression‐free survival in the first‐line treatment of EOC (ICON7, <a href="./references#CD010482-bbs2-0033" title="PerrenTJ , SwartAM , PfistererJ , LedemannJA , Pujade‐LauraineE , KristensenG , and the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine2011;365:2484‐96. ">Perren 2011</a>; GOG 218, <a href="./references#CD010482-bbs2-0007" title="BurgerRA , BradyMF , BookmanMA , FlemingGF , MonkBJ , et al. for the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine2011;365:2473‐83. ">Burger 2011</a>). Bevacizumab appears to benefit primarily women at high risk of disease progression (<a href="./references#CD010482-bbs2-0007" title="BurgerRA , BradyMF , BookmanMA , FlemingGF , MonkBJ , et al. for the Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England Journal of Medicine2011;365:2473‐83. ">Burger 2011</a>; <a href="./references#CD010482-bbs2-0033" title="PerrenTJ , SwartAM , PfistererJ , LedemannJA , Pujade‐LauraineE , KristensenG , and the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine2011;365:2484‐96. ">Perren 2011</a>; ), and its use in clinical practice should be weighed against potential reduction in quality of life (<a href="./references#CD010482-bbs2-0036" title="StarkD , NankivellM , Pujade‐LauraineE , KristensenG , ElitL , StocklerM , et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality‐of‐life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology2013;14(3):236‐43. ">Stark 2013</a>). Ways of improving PAC/carbo scheduling (e.g. by weekly dosing) with or without bevacizumab are currently under investigation (ICON8; GOG 262). </p> <p>Surgery plus standard chemotherapy has a response rate of 70% to 80%. However, 55% to 75% of responders will relapse within two years of treatment completion (<a href="./references#CD010482-bbs2-0029" title="National Institute for Health and Clinical Excellence. Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55). London: National Institute for Health and Clinical Excellence,2003. ">NICE 2003</a>). </p> </section> <section id="CD010482-sec2-0002"> <h3 class="title" id="CD010482-sec2-0002">Description of the intervention</h3> <p>Doxorubicin hydrochloride is a cytotoxic drug that belongs to the anthracycline family and has been available since the 1960s (<a href="./references#CD010482-bbs2-0013" title="European Medicines Agency. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000089/WC500020173.pdf 2010 (accessed 24 January 2013). ">EMA 2010</a>). It was originally used in the first‐line treatment of EOC in the 1970s, when in vitro experiments showed a dose‐response relationship in EOC cell lines. Activity against EOC was subsequently proven in clinical trials (<a href="./references#CD010482-bbs2-0005" title="A'HernR , GoreME . The impact of doxorubicin on survival in advanced ovarian cancer. Journal of Clinical Oncology1995;13:726‐32. ">A'Hern 1995</a>; <a href="./references#CD010482-bbs2-0031" title="Ovarian Cancer Meta‐analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma. Journal of Clinical Oncology1991;9:1668‐74. ">OCMP 1991</a>; <a href="./references#CD010482-bbs2-0032" title="OzolsRF , WilsonJK , WeltzMD , GrotzingerKR , MyersCE , YoungRC . Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Research1980;40:4109‐12. ">Ozols 1980</a>). Despite its potent antineoplastic activity, clinical use of doxorubicin has been limited by its associated side effects, in particular haematological toxicity and irreversible cardiac damage. Pegylated liposomal doxorubicin (PLD) is a formulation of liposomal doxorubicin that is coated in polyethylene glycol (PEG), which reduces the rate at which the active drug is broken down (<a href="./references#CD010482-bbs2-0018" title="GabizonAA . Stealth liposomes and tumour targeting: one step further in the quest for the magic bullet. Clinical Cancer Research2001;7:223‐5. ">Gabizon 2001</a>) and makes it less toxic to heart muscle. </p> <p>In the UK, PLD is currently licensed for the treatment of advanced EOC in women for whom platinum‐based chemotherapy has failed (platinum‐resistant EOC; <a href="./references#CD010482-bbs2-0013" title="European Medicines Agency. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000089/WC500020173.pdf 2010 (accessed 24 January 2013). ">EMA 2010</a>). In these women, PLD may be given intravenously at a dose of 50 mg/m² once every four weeks for six cycles if tolerated, and if the disease does not progress (<a href="./references#CD010482-bbs2-0013" title="European Medicines Agency. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_‐_Summary_for_the_public/human/000089/WC500020173.pdf 2010 (accessed 24 January 2013). ">EMA 2010</a>). However, 50 mg/m² is generally considered to be too toxic; therefore, in clinical practice, lower doses are usually given to reduce drug‐related adverse effects (40 mg/m² as a single agent and 30 mg/m² in combination therapy). The main toxicities associated with PLD are nausea, palmar‐plantar erythema or hand‐foot syndrome (redness and soreness of palms of hands and soles of feet), stomatitis and myelosuppression (<a href="./references#CD010482-bbs2-0024" title="Janssen‐CilagP , Ltd . CAELYX Product Information. http://www.janssen.com.au/Products/Caelyx. Amended 4 January 2011 (accessed 24 January 2013). ">Janssen‐Cilag 2011</a>). </p> <p>PLD in combination with platinum has been shown to be a better alternative to PAC/carbo in women with platinum‐sensitive relapsed disease (<a href="./references#CD010482-bbs2-0008" title="Pujade‐LauraineE , WagnerU , Aavall‐LundqvistE , GebskiV , HeywoodM , VaseyPA , et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum‐sensitive ovarian cancer in late relapse. Journal of Clinical Oncology2010;28(20):3323‐9. ">CALYPSO 2010</a>; <a href="./references#CD010482-bbs2-0020" title="BafaloukosD , LinardouH , AravantinosG , PapadimitriouG , BamiasA , FountzilasG , et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine2010;8:3. ">HeCOG 2010</a>). Compared with standard three‐weekly PAC/carbo treatment, a four‐weekly PLD/carbo regimen results in improved progression‐free survival in these women and is better tolerated. In <a href="./references#CD010482-bbs2-0008" title="Pujade‐LauraineE , WagnerU , Aavall‐LundqvistE , GebskiV , HeywoodM , VaseyPA , et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum‐sensitive ovarian cancer in late relapse. Journal of Clinical Oncology2010;28(20):3323‐9. ">CALYPSO 2010</a>, significantly fewer women experienced complete hair loss, hypersensitivity reactions and neuropathies in the PLD arm compared with the PAC arm, and women in the PLD arm were less likely to discontinue treatment. Because PLD/carbo is a better alternative to PAC/carbo for relapsed EOC, this might also be the case when it is used as first‐line chemotherapy. </p> </section> <section id="CD010482-sec2-0003"> <h3 class="title" id="CD010482-sec2-0003">How the intervention might work</h3> <p>Anthracyclines interact with DNA, adversely affecting all cell functions that rely on DNA. Furthermore, they interact with cell membranes, altering their functions and generating hydrogen peroxide and hydroxy radicals, which are highly destructive to cells (<a href="./references#CD010482-bbs2-0039" title="ZuninoF , PratesiG . Antitumour antibodies. Oxford Textbook of Oncology. 2nd Edition. Oxford, UK: Oxford University Press, 2002:715‐27. ">Zunino 2002</a>). The PEG coating of PLD represents a hydrophilic barrier that protects the liposomes from detection by the reticuloendothelial system and increases the time that the active drug remains in circulation (<a href="./references#CD010482-bbs2-0017" title="GabizonA , MartinF . Polyethylene glycol‐coated (pegylated) liposomal doxorubicin: rationale for use in solid tumours. Drugs1997;54(Suppl 4):15‐21. ">Gabizon 1997</a>; <a href="./references#CD010482-bbs2-0018" title="GabizonAA . Stealth liposomes and tumour targeting: one step further in the quest for the magic bullet. Clinical Cancer Research2001;7:223‐5. ">Gabizon 2001</a>). The size of the liposomes prevents PLD from entering tissues with tight capillary junctions, such as the heart and gastrointestinal tract; therefore it causes less toxicity compared with non‐modified doxorubicin, while leading to increased concentrations within the tumour (<a href="./references#CD010482-bbs2-0038" title="WaterhouseDN , TardiPG , MayerLD , BallyMB . A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Safety2001;24:903‐20. ">Waterhouse 2001</a>). </p> </section> <section id="CD010482-sec2-0004"> <h3 class="title" id="CD010482-sec2-0004">Why it is important to do this review</h3> <p>PLD is a formulation of a proven chemotherapeutic agent with an improved efficacy and safety profile. Good evidence supports its use in the treatment of relapsed EOC, in combination with carboplatin in platinum‐sensitive disease and as a single agent in platinum‐resistant disease (<a href="./references#CD010482-bbs2-0026" title="LawrieTA , BryantA , CameronA , GrayE , MorrisonJ . Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006910.pub2] ">Lawrie 2013</a>). This represents a strong rationale for testing PLD in the first‐line setting. After a large randomised controlled trial (RCT) of PLD/carbo for first‐line treatment of EOC had been completed (<a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>), we considered it important to review the evidence related to PLD as first‐line chemotherapy for newly diagnosed EOC. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010482-sec1-0003" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010482-sec1-0003"></div> <p>To evaluate the role of pegylated liposomal doxorubicin, alone or in combination, in first‐line chemotherapy for women with EOC. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010482-sec1-0004" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010482-sec1-0004"></div> <section id="CD010482-sec2-0005"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010482-sec3-0001"> <h4 class="title">Types of studies</h4> <p>RCTs.</p> </section> <section id="CD010482-sec3-0002"> <h4 class="title">Types of participants</h4> <p>Women (aged 18 and older) with EOC who may or may not have undergone primary cytoreductive surgery. </p> </section> <section id="CD010482-sec3-0003"> <h4 class="title">Types of interventions</h4> <p>PLD (50 mg or less every three or more weeks) alone or in combination with other agent/s (e.g. carbo) versus other agent/s as first‐line chemotherapy. </p> </section> <section id="CD010482-sec3-0004"> <h4 class="title">Types of outcome measures</h4> <section id="CD010482-sec4-0001"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010482-lst1-0001"> <li> <p>Progression‐free survival (PFS): survival until disease progression.</p> </li> </ul> </p> </section> <section id="CD010482-sec4-0002"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010482-lst1-0002"> <li> <p>Overall survival (OS): survival until death from any cause.</p> </li> <li> <p>Severe adverse events, classified according to <a href="./references#CD010482-bbs2-0010" title="CTCAE . Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. ">CTCAE 2006</a>, including specific haematological, gastrointestinal, genitourinary, dermatological, neurological, pulmonary and other severe adverse events. </p> </li> <li> <p>Symptom control (e.g. haematopoietic growth factors, transfusions, antiemetics, dose delays and reductions). </p> </li> <li> <p>Quality of life (QoL).</p> </li> </ul> </p> </section> </section> </section> <section id="CD010482-sec2-0006"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010482-sec3-0005"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases (also see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/GYNAECA/sect0-meta.html" target="_blank">Cochrane Gynaecological Cancer Group</a> methods used in reviews): </p> <p> <ul id="CD010482-lst1-0003"> <li> <p>The Cochrane Gynaecological Cancer Group's Trial Register</p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>MEDLINE</p> </li> <li> <p>EMBASE</p> </li> </ul> </p> <p>The CENTRAL, MEDLINE and EMBASE search strategies, based on terms related to the review topic, are presented in <a href="./appendices#CD010482-sec2-0016">Appendix 1</a>; <a href="./appendices#CD010482-sec2-0017">Appendix 2</a>; and <a href="./appendices#CD010482-sec2-0018">Appendix 3</a>, respectively. As PLD was recently developed, we searched databases for articles published from January 1990 until February 2013. </p> </section> <section id="CD010482-sec3-0006"> <h4 class="title">Searching other resources</h4> <p>We searched the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>), <a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a> and the Physicians Data Query (PDQ) (<a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>) for ongoing trials. We also looked for abstracts of studies presented at relevant scientific meetings from 2000 onwards, including the American Society of Clinical Oncologists (ASCO), the European Society of Medical Oncologists (ESMO) and the European Society of Gynaecologic Oncologists (ESGO) Annual Meetings, using the <a href="http://zetoc.mimas.ac.uk" target="_blank">zetoc.mimas.ac.uk</a> website. When necessary, we contacted the main investigators of relevant trials to request for further information. In addition, we checked the citation lists of included studies to identify other relevant reports/studies. </p> </section> </section> <section id="CD010482-sec2-0007"> <h3 class="title" id="CD010482-sec2-0007">Data collection and analysis</h3> <section id="CD010482-sec3-0007"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database (Reference Manager version 10) and removed duplicates. Two review authors (Theresa A Lawrie (TAL) and Clemens Thoma (CT)) reviewed the remaining records independently to identify potentially relevant trials. We excluded studies that clearly did not meet the inclusion criteria and obtained the full text of potentially relevant trials. Three review authors (CT, TAL and Roy Rabbie (RR)) independently assessed these identified trials for eligibility. Had there been any disagreements related to eligibility, we would have involved Jo Morrison (JM) in the process. For excluded studies, we documented the reasons for exclusion. </p> </section> <section id="CD010482-sec3-0008"> <h4 class="title">Data extraction and management</h4> <p>We designed and piloted a data extraction form for the review. Two review authors (RR and CT) independently extracted data from included studies. These data were checked by TAL. When disagreement arose between reviewers, JM was asked to resolve it. </p> <p>For included studies, we extracted the following data when possible.</p> <p> <ul id="CD010482-lst1-0004"> <li> <p>Author, year of publication and journal citation.</p> </li> <li> <p>Country.</p> </li> <li> <p>Setting.</p> </li> <li> <p>Inclusion and exclusion criteria.</p> </li> <li> <p>Study design, methodology.</p> </li> <li> <p>Duration of follow‐up.</p> </li> <li> <p>Study population:</p> <ul id="CD010482-lst2-0001"> <li> <p>Total number enrolled.</p> </li> <li> <p>Participant characteristics.</p> </li> <li> <p>Age.</p> </li> <li> <p>Comorbidities.</p> </li> </ul> </li> <li> <p>EOC details at diagnosis:</p> <ul id="CD010482-lst2-0002"> <li> <p>FIGO stage.</p> </li> <li> <p>Histological cell type.</p> </li> <li> <p>Tumour grade.</p> </li> <li> <p>Performance status.</p> </li> <li> <p>Extent of disease.</p> </li> </ul> </li> <li> <p>Total number of intervention groups.</p> </li> <li> <p>Intervention details:</p> <ul id="CD010482-lst2-0003"> <li> <p>Details of PLD, including dose, regimen, frequency and number of cycles.</p> </li> <li> <p>Comparison details, including type of control and dose, regimen, frequency and number of cycles. </p> </li> </ul> </li> <li> <p>Proportions of participants who received all/part/none of the intended treatment.</p> </li> <li> <p>Delays in treatment.</p> </li> <li> <p>Risk of bias in study (see <a href="#CD010482-sec3-0009">Assessment of risk of bias in included studies</a>). </p> </li> <li> <p>Outcomes—PFS, OS, QoL, symptom control and adverse events:</p> <ul id="CD010482-lst2-0004"> <li> <p>For each outcome: outcome definition (with diagnostic criteria if relevant).</p> </li> <li> <p>Unit of measurement (if relevant).</p> </li> <li> <p>For scales: upper and lower limits, and whether high or low score is good.</p> </li> <li> <p>Results: number of participants allocated to each intervention group.</p> </li> <li> <p>For each outcome of interest: sample size and missing participants.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD010482-sec3-0009"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included RCTs using The Cochrane Collaboration's tool and the criteria specified in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010482-bbs2-0022" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). This included assessment of the following domains. </p> <p> <ul id="CD010482-lst1-0005"> <li> <p>Selection bias:</p> <ul id="CD010482-lst2-0005"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> </ul> </li> <li> <p>Performance bias:</p> <ul id="CD010482-lst2-0006"> <li> <p>Blinding of participants and personnel (participants and treatment providers).</p> </li> </ul> </li> <li> <p>Detection bias:</p> <ul id="CD010482-lst2-0007"> <li> <p>Blinding of outcome assessment.</p> </li> </ul> </li> <li> <p>Attrition bias:</p> <ul id="CD010482-lst2-0008"> <li> <p>Incomplete outcome data: We recorded the proportion of participants whose outcomes were not reported at the end of the study and considered &gt; 20% attrition to indicate high risk of bias. </p> </li> </ul> </li> <li> <p>Reporting bias:</p> <ul id="CD010482-lst2-0009"> <li> <p>Selective reporting of outcomes.</p> </li> </ul> </li> <li> <p>Other possible sources of bias.</p> </li> </ul> </p> <p>Two review authors (RR and CT) independently applied the 'Risk of bias' tool (<a href="./appendices#CD010482-sec2-0019">Appendix 4</a>), and differences were resolved by discussion or by appeal to a third review author (TAL or JM). We have presented results in a 'Risk of bias' summary graph and have interpreted the results of the meta‐analyses in the light of findings with respect to risk of bias. </p> </section> <section id="CD010482-sec3-0010"> <h4 class="title">Measures of treatment effect</h4> <p>We used the following measures of the effect of treatment.</p> <p> <ul id="CD010482-lst1-0006"> <li> <p>For time‐to‐event data, we used hazard ratios (HRs).</p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events), we extracted the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint to estimate a risk ratio (RR). </p> </li> <li> <p>For continuous outcomes (e.g. QoL measures), we extracted the mean difference (MD) and the standard deviation (SD) between the final value of the outcome measure in each treatment arm at the end of follow‐up. If standard deviations of final values were not available, we used change scores if SDs were available. If no SDs were available, we omitted these trials. </p> </li> </ul> </p> <p>When possible, we extracted data relevant to an intention‐to‐treat analysis (ITT), in which participants were analysed in the groups to which they were assigned. When time‐to‐event outcomes were assessed by more than one method (i.e. independent radiology review, investigator assessment or independent oncology review), we used the independent radiology review data and noted any differences in effect size and direction, compared with the other methods, as reported in the text. </p> </section> <section id="CD010482-sec3-0011"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was usually the individual participant; however, when data were presented per treatment cycle (e.g. for dose delays) we also extracted these data. </p> </section> <section id="CD010482-sec3-0012"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing data.</p> </section> <section id="CD010482-sec3-0013"> <h4 class="title">Assessment of heterogeneity</h4> <p>We did not assess statistical heterogeneity between trials, as trials were insufficient to allow performance of meta‐analyses. In future versions of this review, if meta‐analyses are possible, we will assess heterogeneity by visual inspection of forest plots, by estimation of the percentage of heterogeneity between trials that cannot be ascribed to sampling variation (<a href="./references#CD010482-bbs2-0021" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring Inconsistency in meta‐analysis. BMJ2003;327:557‐60. ">Higgins 2003</a>) and by formal statistical testing of the significance of the heterogeneity (<a href="./references#CD010482-bbs2-0011" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining for heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Healthcare: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001. ">Deeks 2001</a>). In each meta‐analysis, we will regard heterogeneity as substantial if I² is greater than 50% and either T² is greater than zero, or if a low P value (less than 0.10) is obtained in the Chi² test. If evidence of substantial heterogeneity is noted, we will investigate the possible reasons for this and report them. </p> </section> <section id="CD010482-sec3-0014"> <h4 class="title">Data synthesis</h4> <p>We used random‐effects models with inverse variance weighting for all analyses (<a href="./references#CD010482-bbs2-0012" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7:177‐88. ">DerSimonian 1986</a>). As insufficient clinically similar trials were available, we could not perform a meta‐analysis; however, in future versions of this review, we plan to pool trial results as follows. </p> <p> <ul id="CD010482-lst1-0007"> <li> <p>For time‐to‐event data, we will pool HRs using the generic inverse variance facility of <a href="./references#CD010482-bbs2-0034" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>. </p> </li> <li> <p>For dichotomous outcomes, we will pool the RRs.</p> </li> <li> <p>For continuous outcomes, we will pool the mean differences (MDs) between treatment arms at the end of follow‐up if all trials measure the outcome on the same scale; otherwise we will pool standardised mean differences (SMDs).  </p> </li> </ul> </p> </section> <section id="CD010482-sec3-0015"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Trials were insufficient for meta‐analyses of subgroup data; however, we recorded available subgroup data for survival outcomes as follows. </p> <p> <ul id="CD010482-lst1-0008"> <li> <p>Stage of disease: early (FIGO Ia, Ib, Ic, IIa, IIb) and advanced (FIGO III, IV).</p> </li> <li> <p>No residual disease, optimal staging (residual disease ≤ 1 cm), suboptimal staging (residual disease &gt; 1 cm) and no surgery. </p> </li> <li> <p>Age &lt; 70 and ≥ 70 years.</p> </li> </ul> </p> </section> <section id="CD010482-sec3-0016"> <h4 class="title">Sensitivity analysis</h4> <p>Studies were insufficient to allow sensitivity analysis to be performed.</p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010482-sec1-0005" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010482-sec1-0005"></div> <section id="CD010482-sec2-0008"> <h3 class="title">Description of studies</h3> <section id="CD010482-sec3-0017"> <h4 class="title">Results of the search</h4> <p>The search strategy identified a total of 2267 reference hits, which were reduced to 1665 after de‐duplication. By screening titles and abstracts, we identified 16 citations as potentially eligible for this review. After evaluating full texts of these citations, we included two trials (14 citations) and excluded two trials (<a href="#CD010482-fig-0001">Figure 1</a>). An update of the search (Oct 2016) revealed a further 192 unique references. By screening titles and bastracts, we identified xx citations as potentially eligible for the review. fter evaulating full text of these studies, both were excluded and no further studies were included in the review. </p> <div class="figure" id="CD010482-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram of searches to February 2013." data-id="CD010482-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram of searches to February 2013.</p> </div> </div> </div> </section> <section id="CD010482-sec3-0018"> <h4 class="title">Included studies</h4> <p>Two trials, <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> and <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, met the inclusion criteria and contributed data to the analyses. Both were multi‐centre phase III RCTs that randomly assigned 820 and 1726 participants, respectively. <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> compared the combination of three‐weekly PLD/carbo with standard three‐weekly PAC/carbo, whereas <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a> compared a triplet combination of PAC/carbo/PLD with the same standard therapy. We attempted to contact the investigators of both trials to obtain additional information and data. The investigators of <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> responded and supplied unpublished updated survival and subgroup data for this review. The trials are described below and in the <a href="./references#CD010482-sec2-0022" title="">Characteristics of included studies</a> section of the review. </p> <p><i>Participants</i> </p> <p>Both trials included women with histologically proven advanced EOC; however, <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a> also included women with primary peritoneal carcinoma (similar in histology and treatment to the most common histological subtype of EOC) (13%). <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> included stages Ic to IV and <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a> stages III to IV, according to the FIGO scoring system. However, less than 20% of the women in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> had FIGO stage I/II disease. Median age and histological characteristics were comparable between the two trials. All women in <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a> had undergone primary cytoreduction, whereas 18% of women in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> had had no surgery. Twenty‐eight per cent and 30% of women in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> and <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, respectively, had undergone suboptimal cytoreduction, as defined by residual tumour &gt; 1 cm. </p> <p><i>Interventions</i> </p> <p>Women in the standard treatment arms of both trials received carboplatin (dosed according to the Calvert formula) and paclitaxel (175 mg/m²) every three weeks. In the experimental treatment arms, PLD was given intravenously on day one at a dose of 30 mg/m² in both trials. In <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>, PLD was administered every three weeks, whereas in <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, women received PLD only on alternate cycles (i.e. 6‐weekly). Women in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> underwent three cycles of treatment, and those with stable or responding disease continued for a further three cycles. In <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, women were assigned to eight cycles of chemotherapy, and at least four cycles of carboplatin and paclitaxel were maintained in the standard and experimental arms. </p> <p><i>Outcomes</i> </p> <p>In both studies, PFS and OS were the primary and secondary outcomes, respectively, and adverse events were reported as graded by National Cancer Institute Common Toxicity Criteria version 2.0 (<a href="./references#CD010482-bbs2-0010" title="CTCAE . Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. ">CTCAE 2006</a>). In addition, <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> evaluated response in accordance with Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0 (<a href="./references#CD010482-bbs2-0037" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>) and quality of life using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ‐C30) (<a href="./references#CD010482-bbs2-0006" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al. The European Organization for Research and Treatment of Cancer QLQ‐C30: a quality‐of‐life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute1993;85(5):365‐76. ">Aaronson 1993</a>). In <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, toxicities were reported in the form of a bar chart with the number of participants (%) as the y‐axis. As more detailed data were not available, we used the data from this bar chart to estimate the relative rates of toxicity in each treatment arm. </p> </section> <section id="CD010482-sec3-0019"> <h4 class="title">Excluded studies</h4> <p>We excluded two studies because they were not RCTs (see <a href="./references#CD010482-sec2-0023" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD010482-sec2-0009"> <h3 class="title">Risk of bias in included studies</h3> <p>In general, we considered the two included studies to be at low risk of bias. Both were large, multi‐centre, international studies with central and regional coordinating offices. For <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>, randomisation was computer‐generated with allocation by central telephone assignment (low risk of selection bias), attrition was low except for quality of life data (low risk of attrition bias), prespecified and expected outcomes were reported (low risk of reporting bias) and baseline characteristics were similar between groups. For <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, allocation concealment was not clearly stated, and we were unable to obtain this information from the authors. However, randomisation was computer‐generated in stratified blocks, attrition was low, prespecified and expected outcomes were reported and baseline characteristics were similar in both of the extracted arms. Both included studies were open‐label studies, and independent outcome evaluation was not described in either study; this may have predisposed these trials to performance or detection bias, or both (high risk of performance bias). </p> </section> <section id="CD010482-sec2-0010"> <h3 class="title" id="CD010482-sec2-0010">Effects of interventions</h3> <p>See: <a href="./full#CD010482-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD010482-sec3-0020"> <h4 class="title">PLD/carbo versus PAC/carbo</h4> <p>Only one trial (<a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>), which included 820 women with newly diagnosed EOC, contributed data for this comparison. We used updated, unpublished survival data (August 2013) that we obtained from the <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> investigators for this review. </p> <section id="CD010482-sec4-0003"> <h5 class="title">Survival</h5> <p>Overall, no statistically significant differences were noted between the PLD/carbo arm and the PAC/carbo arm with respect to PFS (HR 1.01; 95% CI 0.85 to 1.19; <a href="./references#CD010482-fig-00101" title="">Analysis 1.1</a>; high‐quality evidence) or OS (HR 0.94; 95% CI 0.78 to 1.13; <a href="./references#CD010482-fig-00102" title="">Analysis 1.2</a>; high‐quality evidence). </p> <p>Exploratory 'ad hoc' subgroup analyses performed by the investigators revealed no significant differences between comparison arms in any of the subgroup analyses (Eastern Cooperative Oncology Group Performance Status (ECOG PS), age, stage, tumour histology and residual disease). </p> <p>Further exploratory subgroup analyses were performed by the <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> investigators upon our request, in which participants were separated into low‐ and high‐risk groups according to FIGO stage and residual disease (women with stage IV disease or stage III with residual disease &gt; 1 cm were considered at high risk of disease progression). No significant differences in PFS and OS results were noted between treatment arms for participants included in different risk groups. </p> </section> <section id="CD010482-sec4-0004"> <h5 class="title">Toxicity</h5> <p>Women in the PLD/carbo arm compared with the PAC/carbo arm were significantly <i>more</i> likely to experience the following. </p> <p> <ul id="CD010482-lst1-0009"> <li> <p>Anaemia (grade 3/4): RR 2.74; 95% CI 1.54 to 4.88 (<a href="./references#CD010482-fig-00107" title="">Analysis 1.7</a>). </p> </li> <li> <p>Thrombocytopenia (grade 3/4): RR 8.09; 95% CI 3.93 to 16.67 (<a href="./references#CD010482-fig-00108" title="">Analysis 1.8</a>). </p> </li> </ul> </p> <p>And they were significantly <i>less</i> likely to experience these conditions. </p> <p> <ul id="CD010482-lst1-0010"> <li> <p>Alopecia (grade 2): RR 0.09; 95% CI 0.06 to 0.14 (<a href="./references#CD010482-fig-00109" title="">Analysis 1.9</a>). </p> </li> <li> <p>Neuropathy (grade 3/4): RR 0.09; 95% CI 0.01 to 0.66 (<a href="./references#CD010482-fig-00113" title="">Analysis 1.13</a>). </p> </li> </ul> </p> <p>Although the risk ratio of neutropenia (grade 3/4) seemed to favour the PLD/carbo arm (RR 0.87; 95% CI 0.75 to 1.01), this did not translate into a statistically significant reduction in febrile neutropenia. No statistically significant differences were noted between study arms in the risk ratio of other severe adverse events, including allergic reactions, vomiting, stomatitis, hand‐foot syndrome and treatment‐related death (2 vs 4 deaths in the PLD vs PAC arm, respectively). </p> </section> <section id="CD010482-sec4-0005"> <h5 class="title">Dose delays and discontinuation</h5> <p>Women in the PLD/carbo arm were more likely to experience dose delays than women in the standard treatment arm (3636 cycles; RR 3.01; 95% CI 2.61 to 3.47; <a href="./references#CD010482-fig-00117" title="">Analysis 1.17</a>) and were more likely to discontinue treatment as the result of toxicity or refusal (RR 1.83; 95% CI 1.09 to 3.07; <a href="./references#CD010482-fig-00118" title="">Analysis 1.18</a>). The most frequent cause of toxicity related to delays was reported to be haematological toxicity. </p> </section> <section id="CD010482-sec4-0006"> <h5 class="title">Quality of life</h5> <p>Global quality of life scores were not statistically significantly different between the two groups, although these data suffered from high attrition rates. </p> </section> </section> <section id="CD010482-sec3-0021"> <h4 class="title">PLD/PAC/carbo versus PAC/carbo</h4> <p>Only one trial (<a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>), which included 1726 women with newly diagnosed EOC, contributed data for this comparison. </p> <section id="CD010482-sec4-0007"> <h5 class="title">Survival</h5> <p>No statistically significant differences between the PLD/PAC/carbo arm and the PAC/carbo arm were noted with respect to PFS (HR 0.98; 95% CI 0.88 to 1.09; <a href="./references#CD010482-fig-00101" title="">Analysis 1.1</a>) or OS (HR 0.95; 95% CI 0.84 to 1.08; <a href="./references#CD010482-fig-00102" title="">Analysis 1.2</a>). The results of any potential subgroup analyses were not available for this review. </p> </section> <section id="CD010482-sec4-0008"> <h5 class="title">Toxicity</h5> <p>Women in the PLD/PAC/carbo arm compared with the PAC/carbo arm were significantly <i>more</i> likely to experience the following. </p> <p> <ul id="CD010482-lst1-0011"> <li> <p>Febrile neutropenia (grade 3/4): RR 2.25; 95% CI 1.72 to 2.94 (<a href="./references#CD010482-fig-00105" title="">Analysis 1.5</a>). </p> </li> <li> <p>Neutropenia (grade 4): RR 1.13; 95% CI 1.06 to 1.22 (<a href="./references#CD010482-fig-00106" title="">Analysis 1.6</a>). </p> </li> <li> <p>Anaemia (grade 3/4): RR 1.79; 95% CI 1.40 to 2.30 (<a href="./references#CD010482-fig-00107" title="">Analysis 1.7</a>). </p> </li> <li> <p>Thrombocytopenia (grade 3/4): RR 1.73; 95% CI 1.49 to 2.01 (<a href="./references#CD010482-fig-00108" title="">Analysis 1.8</a>). </p> </li> </ul> </p> </section> <section id="CD010482-sec4-0009"> <h5 class="title">Dose delays and discontinuation</h5> <p>No statistically significant differences were noted between the PLD/PAC/carbo and PAC/carbo arms with regard to discontinuation due to toxicity or refusal (RR 1.30; 95% CI 0.98 to 1.74; <a href="./references#CD010482-fig-00118" title="">Analysis 1.18</a>), although the point estimate favours PAC/carbo. </p> </section> <section id="CD010482-sec4-0010"> <h5 class="title">Quality of life</h5> <p>These data were not available.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010482-sec1-0006" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010482-sec1-0006"></div> <section id="CD010482-sec2-0011"> <h3 class="title" id="CD010482-sec2-0011">Summary of main results</h3> <p><b>PLD/carbo versus PAC/carbo</b> </p> <p>We included one large study of women with advanced EOC, which used a PLD dose of 30 mg/m² in the experimental arm in combination with carboplatin every three weeks. No statistically significant differences in survival outcomes (PFS and OS) were reported between the treatment arms. PLD/carbo was associated with significantly more anaemia and thrombocytopenia than was PAC/carbo, whereas PAC/carbo was associated with significantly more alopecia and neuropathy. Women receiving PLD/carbo were significantly more likely to experience dose delays than women in the standard treatment arm and were significantly more likely to discontinue treatment as the result of toxicity or refusal. </p> <p><b>PLD/PAC/carbo versus PAC/carbo</b> </p> <p>We included one study, which used a PLD dose of 30 mg/m² administered in alternate cycles (every six weeks) only as part of a triplet regimen in combination with paclitaxel and carboplatin. The addition of PLD to the combination of PAC/carbo produced no additional survival benefit over the standard regimen. However, the experimental triplet was associated with significantly more haematological toxicity, including anaemia, thrombocytopenia, neutropenia and febrile neutropenia. </p> </section> <section id="CD010482-sec2-0012"> <h3 class="title" id="CD010482-sec2-0012">Overall completeness and applicability of evidence</h3> <p>We consider the evidence sufficient to show that PLD/carbo is as effective with regard to survival outcomes as the standard PAC/carbo regimen in first‐line chemotherapy for women with advanced EOC. This effect appears to apply equally to women at lower and higher risk of disease progression, based on the stage and amount of residual disease present. </p> <p>We did not prespecify subgrouping of the review results by performance status and histology. These subgroups were reported by <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>, however, and these investigators reported no significant differences between treatment groups in either subgroup analysis. </p> <p>With regard to the triplet regimen of PLD/PAC/carbo, we consider current evidence provided by the <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a> trial to be sufficient to show that no additional survival benefit is derived by adding PLD to the standard regimen on alternate cycles. Although the overall PLD dose intensity of this regimen was suboptimal (5 mg/m²/wk), further research using three‐weekly cycling (instead of six‐weekly cycling) is unlikely to be conducted, given the high rates of haematological toxicity experienced by women in this trial. </p> <p>No RCTs have evaluated single‐agent PLD for first‐line treatment of EOC, probably because platinum‐based therapy is well established. However, PLD alone may be useful for women in whom platinum therapy is unsuitable (e.g. those with platinum hypersensitivity or renal dysfunction). This requires further investigation. Research efforts are currently focused in part on improving the scheduling of PAC/carbo, as weekly paclitaxel alongside three‐weekly carboplatin may be more effective (<a href="./references#CD010482-bbs2-0025" title="KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al. Dose‐dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open‐label, randomised controlled trial. The Lancet2009;374(9698):1331‐8. ">Katsumata 2009</a>). Similarly, improvements in PLD/carbo scheduling might reduce adverse events associated with this drug combination. </p> </section> <section id="CD010482-sec2-0013"> <h3 class="title" id="CD010482-sec2-0013">Quality of the evidence</h3> <p>We considered the evidence regarding survival for PLD/carbo versus PAC/carbo to be of high quality (see <a href="./full#CD010482-tbl-0001">summary of findings Table for the main comparison</a>). Although the published <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> trial analysis was performed when fewer events had occurred than planned (556 instead of 632 PFS events), we obtained updated data from the investigators in August 2013, which support the earlier findings. </p> <p>With regard to <a href="./references#CD010482-bbs2-0001" title="BookmanMA . Erratum. Journal of Clinical Oncology2009;27(13):2305. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol. 24, 18S (June 20 Suppl):5002. Bookman MA and the Gynecologic Cancer InterGroup (GCIG). GOG0182‐ICON5: 5‐arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG‐lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced‐stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma [abstract]. Journal of Clinical Oncology2006;24(Suppl 18):A‐5002:256s. BookmanMA , BradyMF , McGuireWP , HarperPG , AlbertsDS , FriedlanderM , et al. Evaluation of new platinum‐based treatment regimens in advanced‐stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of Clinical Oncology2009;27(9):1419‐25. BookmanMA , GreerBE , OzolsRF . Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182‐ICON5. International Journal of Gynecological Cancer2003;13(6):735‐40. Copeland LJB and the Gynecologic Cancer Intergroup (GCIG). Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182‐ICON5. Gynecologic Oncology2003;90:(2 Part 2):S1‐7. ">GOG0182/ICON 5 2009</a>, although the quality of evidence related to alternate cycle dosing of PLD is high, we downgraded the quality of survival outcome effects to moderate because of the limited applicability of these results. </p> <p>In general, we considered the quality of evidence related to severe adverse events to be high; although only two contributing studies were identified, the numbers of women enrolled in these well‐conducted trials were adequate to allow evaluation of the relative risks of common adverse events. </p> </section> <section id="CD010482-sec2-0014"> <h3 class="title" id="CD010482-sec2-0014">Potential biases in the review process</h3> <p>To our knowledge, no biases were present in the review process.</p> </section> <section id="CD010482-sec2-0015"> <h3 class="title" id="CD010482-sec2-0015">Agreements and disagreements with other studies or reviews</h3> <p>In a recent review and meta‐analysis of PLD for relapsed EOC, PLD/carbo administered every four weeks was found to be better than standard three‐weekly PAC/carbo for the treatment of relapsed platinum‐sensitive disease, with respect to survival and adverse events (<a href="./references#CD010482-bbs2-0026" title="LawrieTA , BryantA , CameronA , GrayE , MorrisonJ . Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD006910.pub2] ">Lawrie 2013</a>). Two well‐conducted studies including 1164 women (<a href="./references#CD010482-bbs2-0008" title="Pujade‐LauraineE , WagnerU , Aavall‐LundqvistE , GebskiV , HeywoodM , VaseyPA , et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum‐sensitive ovarian cancer in late relapse. Journal of Clinical Oncology2010;28(20):3323‐9. ">CALYPSO 2010</a>; <a href="./references#CD010482-bbs2-0020" title="BafaloukosD , LinardouH , AravantinosG , PapadimitriouG , BamiasA , FountzilasG , et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine2010;8:3. ">HeCOG 2010</a>) contributed data to these meta‐analyses, which found that women receiving PLD/carbo had an average increase in PFS of 15% (95% CI 3 to 26) compared with women receiving PAC/carbo for relapsed platinum‐sensitive disease. As was found in the present review, the risk ratio of severe haematological adverse events was significantly higher in the PLD/carbo arm than in the PAC/carbo arm. However, the associated risk ratio of thrombocytopenia was substantially lower with PLD/carbo in the recurrent EOC review (RR 2.69 vs RR 8.09). Furthermore, women in the recurrent EOC review were more likely to discontinue treatment as the result of toxicity/refusal if they received PAC/carbo, conversely to the present review. </p> <p>These discrepancies between the adverse event findings of these reviews are most likely due to differences in dose densities of PLD: Three‐weekly cycles of PLD (30 mg/m²) were used in the first‐line treatment study (<a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>), whereas four‐weekly cycles (30 mg/m²) were used in <a href="./references#CD010482-bbs2-0008" title="Pujade‐LauraineE , WagnerU , Aavall‐LundqvistE , GebskiV , HeywoodM , VaseyPA , et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum‐sensitive ovarian cancer in late relapse. Journal of Clinical Oncology2010;28(20):3323‐9. ">CALYPSO 2010</a>. The use of additional therapies for supportive care (e.g. granulocyte colony stimulating factor [G‐CSF], erythropoietin) and, possibly, differences in the indications for discontinuation of treatment due to toxicity may also have contributed to these findings. </p> <p>Similar to the findings of <a href="./references#CD010482-bbs2-0008" title="Pujade‐LauraineE , WagnerU , Aavall‐LundqvistE , GebskiV , HeywoodM , VaseyPA , et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum‐sensitive ovarian cancer in late relapse. Journal of Clinical Oncology2010;28(20):3323‐9. ">CALYPSO 2010</a> and <a href="./references#CD010482-bbs2-0020" title="BafaloukosD , LinardouH , AravantinosG , PapadimitriouG , BamiasA , FountzilasG , et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Medicine2010;8:3. ">HeCOG 2010</a>, the occurrence of severe hand‐foot syndrome was not a significant problem in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>. <a href="./references#CD010482-bbs2-0008" title="Pujade‐LauraineE , WagnerU , Aavall‐LundqvistE , GebskiV , HeywoodM , VaseyPA , et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum‐sensitive ovarian cancer in late relapse. Journal of Clinical Oncology2010;28(20):3323‐9. ">CALYPSO 2010</a> and <a href="./references#CD010482-bbs2-0027" title="MarkmanM , MoonJ , WilczynskiS , LopezAM , RowlandKM , MichelinDP , et al. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecologic Oncology2010;116(3):323‐5. ">Markman 2010</a> also reported lower rates of platinum‐associated hypersensitivity reactions (HSRs) with PLD/carbo; however, this was not a finding of <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a>. </p> <p>ICON7 (<a href="./references#CD010482-bbs2-0033" title="PerrenTJ , SwartAM , PfistererJ , LedemannJA , Pujade‐LauraineE , KristensenG , and the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine2011;365:2484‐96. ">Perren 2011</a>) reported a statistically significant improvement in PFS when bevacizumab was added to PAC/carbo compared with PAC/carbo alone. This improvement with bevacizumab was greatest in women at high risk for progression (15.9 vs 10.5 months; HR 0.68; P &lt; 0.001; <a href="./references#CD010482-bbs2-0033" title="PerrenTJ , SwartAM , PfistererJ , LedemannJA , Pujade‐LauraineE , KristensenG , and the ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine2011;365:2484‐96. ">Perren 2011</a>). For a similarly defined high‐risk group, <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> investigators found no significant difference in PFS (11.8 vs 11 months; HR 0.97; P = 0.8; unpublished data). This suggests that bevacizumab plus PAC/carbo may be associated with improved survival compared with PLD/carbo. Final survival results of ICON7 are awaited with interest. A network meta‐analysis that directly and indirectly compares the various chemotherapy options available for the treatment of primary EOC is needed to clarify the relative effectiveness of these regimens and to guide future research. Network meta‐analysis was outside the scope of this review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010482-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram of searches to February 2013." data-id="CD010482-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram of searches to February 2013.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 1 PFS." data-id="CD010482-fig-00101" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 1 PFS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 2 OS." data-id="CD010482-fig-00102" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 2 OS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 3 PFS: subgroup analyses." data-id="CD010482-fig-00103" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 3 PFS: subgroup analyses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 4 OS: subgroup analyses." data-id="CD010482-fig-00104" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 4 OS: subgroup analyses.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 5 Febrile neutropenia (grade 3/4)." data-id="CD010482-fig-00105" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 5 Febrile neutropenia (grade 3/4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 6 Neutropenia (grade 3/4)." data-id="CD010482-fig-00106" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 6 Neutropenia (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 7 Anaemia (grade 3/4)." data-id="CD010482-fig-00107" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 7 Anaemia (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 8 Thrombocytopenia (grade 3/4)." data-id="CD010482-fig-00108" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 8 Thrombocytopenia (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 9 Alopecia (grade 2)." data-id="CD010482-fig-00109" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 9 Alopecia (grade 2).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 10 Vomiting (grade 3/4)." data-id="CD010482-fig-00110" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 10 Vomiting (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 11 Stomatitis (grade 3/4)." data-id="CD010482-fig-00111" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 11 Stomatitis (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 12 Hand‐foot syndrome (grade 3/4)." data-id="CD010482-fig-00112" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 12 Hand‐foot syndrome (grade 3/4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 13 Neuropathy (grade 3/4)." data-id="CD010482-fig-00113" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 13 Neuropathy (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 14 Allergic reaction (grade 3/4)." data-id="CD010482-fig-00114" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 14 Allergic reaction (grade 3/4). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 15 Fatigue (grade 3/4)." data-id="CD010482-fig-00115" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 15 Fatigue (grade 3/4).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 16 Treatment‐related death." data-id="CD010482-fig-00116" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 16 Treatment‐related death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 17 Dose delays." data-id="CD010482-fig-00117" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 17 Dose delays.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010482-fig-00118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/urn:x-wiley:14651858:media:CD010482:CD010482-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_t/tCD010482-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 PLD combination versus PAC/carbo, Outcome 18 Discontinuation due to toxicity or refusal." data-id="CD010482-fig-00118" src="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 PLD combination versus PAC/carbo, Outcome 18 Discontinuation due to toxicity or refusal. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-fig-00118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/media/CDSR/CD010482/image_n/nCD010482-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010482-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>PLD/carbo compared with PAC/carbo for first‐line treatment of epithelial ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> women with newly diagnosed EOC (stage Ic to IV) </p> <p><b>Settings:</b> hospital </p> <p><b>Intervention:</b> PLD (30 mg/m²)/carbo every three weeks </p> <p><b>Comparison:</b> PAC/carbo every three weeks </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Assumed risk*</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>Corresponding risk</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PFS</b>¹ </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.01</p> <p>(0.85 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OS</b>² </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HR 0.94</p> <p>(0.78 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>820</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anaemia (grade 3/4)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>37 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>100 per 1000</p> <p>(57 to 181)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.74</p> <p>(1.54 to 4.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thrombocytopenia (grade 3/4)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>162 per 1000</p> <p>(79 to 333)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 8.09</p> <p>(3.93 to 16.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Alopecia (grade 2)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>595 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>54 per 1000</p> <p>(36 to 83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09</p> <p>(0.06 to 0.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Neuropathy (grade 3/4)</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 1000</p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 1000</p> <p>(0 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.09</p> <p>(0.01 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>803<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The assumed risk is the median risk for the control group in the one included study. <b>CI:</b> Confidence interval; <b>HR:</b> Hazard Ratio; <b>RR:</b> Risk Ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence:<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>¹Relative median PFS in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> (all participants) was 16.8 months and 19.0 months for PAC/carbo and PLD/carbo, respectively (published 2011 data). <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> also performed exploratory analyses of a high‐risk group (defined as stage IV, or stage III with residual disease &gt; 1 cm). The relative median PFS for this high‐risk group was 11 versus 11.8 months for PAC/carbo and PLD/carbo, respectively (unpublished 2013 data). </p> <p>²Relative median OS in <a href="./references#CD010482-bbs2-0002" title="PignataS , ScambiaG , FerrandinaG , SavareseA , SorioR , BredaE , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first‐line treatment for patients with ovarian cancer: the MITO‐2 randomized phase III trial. Journal of Clinical Oncology2011;29(27):3628‐35. PignataS , ScambiaG , SavareseA , BredaE , ScolloP , DeVivoR , et al. Safety of a 3‐weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO‐2 randomized trial. BioMedCentral (BMC) Cancer2006;6:202. http://www.biomedcentral.com/1471‐2407/6/202.. PignataS , ScambiaG , SavareseA , BredaE , SorioR , PisanoC , et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO‐2 phase III trial. Oncology2009;76(1):49‐54. PignataS , ScambiaG , SavareseA , BredaE , SorioR , Vernaglia LombardiA , et al. Carboplatin plus paclitaxel versus carboplatin plus Stealth liposomal doxorubicin in patients with advanced ovarian cancer: preliminary activity results of the MITO‐2 randomized multicenter trial [Abstract]. Journal of Clinical Oncology; 2007 ASCO Annual Meeting. 2007; Vol. 25:18S(abstract 5532). PignataS , ScambiaG , SavareseA , SorioR , BredaE , FerrandinaG , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): activity and safety results of the MITO‐2 randomized multicenter trial [abstract]. Journal of Clinical Oncology; 2009 ASCO Annual Meeting. 2009; Vol. 27:15S(Suppl; abstract LBA5508). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2010 ASCO Annual Meeting. 2010; Vol. 28:18s, 2010 (Suppl; abstract LBA5033). PignataS , ScambiaG , SavareseA , SorioR , BredaE , LeggeF , et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as firstline treatment for patients with ovarian cancer: the MITO‐2 (multicentre Italian trials in ovarian cancer) randomized phase III trial. Annals of Oncology; 35th ESMO Congress, Milan, Italy. 2010. PignataS , ScambiaG , SavareseA , ZagonelV , GebbiaV , ScolloP , et al. Carboplatin plus paclitaxel (CP) versus carboplatin plus Stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): preliminary safety results of the MITO‐2 randomized multicenter trial. Journal of Clinical Oncology; 2005 ASCO Annual Meeting. 2005; Vol. 23:16S (Suppl, abstract 5014). ">MITO‐2 2011</a> (all participants) was 53.2 months and 61.6 months for PAC/carbo and PLD/carbo, respectively (published 2011 data). The relative median PFS for the high‐risk group defined above was 29 months versus 30.3 months for PAC/carbo and PLD/carbo, respectively (unpublished 2013 data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/full#CD010482-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010482-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PLD combination versus PAC/carbo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 PFS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 OS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PFS: subgroup analyses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 No residual disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Residual disease ≤ 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.96, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Residual disease &gt; 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 No cytoreductive surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.72, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Stage I/II only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.56, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Stage III/IV only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.84, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Age &lt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.80, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Age ≥ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.92, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 OS: subgroup analyses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 No residual disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.49, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Residual disease ≤ 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.94, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Residual disease &gt; 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.60, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 No cytoreductive surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.73, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Stage I/II only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.38, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Stage III/IV only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Age &lt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Age ≥ 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.53, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Febrile neutropenia (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.18, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.72, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neutropenia (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.06, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Anaemia (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.74 [1.54, 4.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.40, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Thrombocytopenia (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.09 [3.93, 16.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.49, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Alopecia (grade 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.06, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Vomiting (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.56, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Stomatitis (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.19, 22.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Hand‐foot syndrome (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.27, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Neuropathy (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.89, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Allergic reaction (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.38, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Fatigue (grade 3/4) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.45, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Treatment‐related death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.09, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Dose delays <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [2.61, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Discontinuation due to toxicity or refusal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 PLD/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.09, 3.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 PLD/PAC/carbo versus PAC/carbo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.98, 1.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">PLD combination versus PAC/carbo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010482.pub2/references#CD010482-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010482.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010482-note-1209">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010482-note-1207">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010482-note-1208">Français</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010482-note-1206">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010482\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010482\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010482\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010482\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010482\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010482.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010482.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010482.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010482.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010482.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725095305"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010482.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725095308"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010482.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e72e0693d1be5',t:'MTc0MDcyNTA5NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 